Peptide nucleic acids targeting miR-221 modulate p27Kip1 expression in breast cancer MDA-MB-231 cells

Brognara,Eleonora; Fabbri,Enrica; Aimi,Fabio; Manicardi,Alex; Bianchi,Nicoletta; Finotti,Alessia; Breveglieri
,Giulia; Borgatti,Monica; Corradini,Roberto; Marchelli,Rosangela; Gambari,Roberto

doi:10.3892/ijo.2012.1632

Peptide nucleic acids targeting miR-221 modulate p27Kip1 expression in breast cancer MDA-MB-231 cells

Authors:
- Eleonora Brognara
- Enrica Fabbri
- Fabio Aimi
- Alex Manicardi
- Nicoletta Bianchi
- Alessia Finotti
- Giulia Breveglieri
- Monica Borgatti
- Roberto Corradini
- Rosangela Marchelli
- Roberto Gambari
View Affiliations

Affiliations: BioPharmaNet, Department of Biochemistry and Molecular Biology, Ferrara University, Ferrara, Italy, Department of Organic and Industrial Chemistry, University of Parma, Parma, Italy, Laboratory for the Development of Pharmacological and Pharmacogenomic Therapy of Thalassaemia, Biotechnology Center, Ferrara University, Ferrara, Italy
Published online on: September 19, 2012 https://doi.org/10.3892/ijo.2012.1632
Pages: 2119-2127

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The activity of a peptide nucleic acid (PNA) targeting cancer-associated microRNA-221 is described. PNAs against miR-221 were designed in order to bind very efficiently to the target RNA strand and to undergo efficient uptake in the cells. A polyarginine-PNA conjugate targeted against miR-221 (Rpep-PNA-a221) showed both very high affinity for RNA and efficient cellular uptake without the addition of transfection reagents. Unmodified PNA with the same sequence displayed RNA binding, but cellular uptake was very poor. Consistently, only Rpep-PNA-a221 strongly inhibited miR-221. Targeting miR-221 by PNA resulted in i) lowering of the hybridization levels of miR-221 measured by RT-qPCR, ii) upregulation of p27Kip1 gene expression, measured by RT-qPCR and western blot analysis. The major conclusion of this study is that efficient delivery of anti‑miR PNA through a suitable peptide carrier (Rpep‑PNA-a221) leads to inhibition of miR-221 activity, altering the expression of miR-221-regulated functions in breast cancer cells.

View Figures

View References

1.	Filipowicz W, Jaskiewicz L, Kolb FA and Pillai RS: Post-transcriptional gene silencing by siRNAs and miRNAs. Curr Opin Struct Biol. 15:331–341. 2005. View Article : Google Scholar : PubMed/NCBI
2.	He L and Hannon GJ: MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2010. View Article : Google Scholar : PubMed/NCBI
3.	Kozomara A and Griffiths-Jones S: miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 39:D152–D157. 2011. View Article : Google Scholar : PubMed/NCBI
4.	Krol J, Loedige I and Filipowicz W: The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 11:597–610. 2010.PubMed/NCBI
5.	Cho WCS: OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer. 6:602007. View Article : Google Scholar : PubMed/NCBI
6.	Edmonds MD, Hurst DR and Welch DR: Linking metastasis suppression with metastamiR regulation. Cell Cycle. 17:2673–2675. 2009. View Article : Google Scholar : PubMed/NCBI
7.	Shah MY and Calin GA: MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer. Genome Med. 3:56–68. 2011. View Article : Google Scholar : PubMed/NCBI
8.	Zhang CZ, Zhang JX, Zhang AL, et al: MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Cancer. 9:2292010. View Article : Google Scholar : PubMed/NCBI
9.	Fu X, Wang Q, Chen J, et al: Clinical significance of miR-221 and its inverse correlation with p27Kip¹ in hepatocellular carcinoma. Mol Biol Rep. 38:3029–3035. 2011. View Article : Google Scholar : PubMed/NCBI
10.	Park JK, Lee EJ, Esau C and Schmittgen TD: Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas. 38:e190–e199. 2009. View Article : Google Scholar : PubMed/NCBI
11.	Kanemaru H, Fukushima S, Yamashita J, et al: The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J Dermatol Sci. 3:187–193. 2011. View Article : Google Scholar : PubMed/NCBI
12.	Frenquelli M, Muzio M, Scielzo C, et al: MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. Blood. 19:3949–3959. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Visone R, Russo L, Pallante P, et al: MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer. 14:791–798. 2007. View Article : Google Scholar : PubMed/NCBI
14.	Zheng C, Yinghao S and Li J: MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2. Med Oncol. 29:815–822. 2012. View Article : Google Scholar : PubMed/NCBI
15.	Zhang C, Zhang J, Zhang A, Wang Y, Han L, You Y, Pu P and Kang C: PUMA is a novel target of miR-221/222 in human epithelial cancers. Int J Oncol. 6:1621–1626. 2010.PubMed/NCBI
16.	Chun-Zhi Z, Lei H, An-Ling Z, et al: MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer. 10:3672010. View Article : Google Scholar : PubMed/NCBI
17.	Lu X, Zhao P, Zhang C, et al: Analysis of miR-221 and p27 expression in human gliomas. Mol Med Rep. 4:651–656. 2009.PubMed/NCBI
18.	Zhang C, Kang C, You Y, et al: Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27^kip1 in vitro and in vivo. Int J Oncol. 34:1653–1660. 2009.PubMed/NCBI
19.	Le Sage C, Nagel R, Egan DA, et al: Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 26:3699–3708. 2007.PubMed/NCBI
20.	Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafrè SA and Farace MG: miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem. 282:23716–23724. 2007. View Article : Google Scholar : PubMed/NCBI
21.	Marin VL, Roy S and Armitage BA: Recent advances in the development of peptide nucleic acid as a gene-targeted drug. Expert Opin Biol Ther. 4:337–348. 2004. View Article : Google Scholar : PubMed/NCBI
22.	Pession A, Tonelli R, Fronza R, et al: Targeted inhibition of NMYC by peptide nucleic acid (PNA) in N-myc amplified human neuroblastoma cells: cell-cycle inhibition with induction of neuronal cell differentiation and apoptosis. Int J Oncol. 24:265–272. 2004.PubMed/NCBI
23.	Gambari R: Biological activity and delivery of peptide nucleic acids (PNA)-DNA chimeras for transcription factor decoy (TFD) pharmacotherapy. Curr Med Chem. 11:1253–1263. 2004. View Article : Google Scholar : PubMed/NCBI
24.	Nielsen PE, Egholm M, Berg RH and Buchardt O: Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science. 254:1497–1500. 1991. View Article : Google Scholar : PubMed/NCBI
25.	Nastruzzi C, Cortesi R, Esposito E, et al: Liposomes as carriers for DNA-PNA hybrids. J Control Release. 68:237–249. 2000. View Article : Google Scholar : PubMed/NCBI
26.	Paulasova P and Pellestor F: The peptide nucleic acids (PNAs): a new generation of probes for genetic and cytogenetic analyses. Ann Genet. 47:349–358. 2004. View Article : Google Scholar : PubMed/NCBI
27.	Karkare S and Bhatnagar D: Promising nucleic acid analogs and mimics: characteristic features and applications of PNA, LNA, and morpholino. Appl Microbiol Biotechnol. 71:575–586. 2006. View Article : Google Scholar : PubMed/NCBI
28.	Menchise V, De Simone G, Tedeschi T, et al: Insights into peptide nucleic acid (PNA) structural features: the crystal structure of a D-lysine-based chiral PNA-DNA duplex. Proc Natl Acad Sci USA. 100:12021–12026. 2003. View Article : Google Scholar : PubMed/NCBI
29.	Nielsen PE: Antisense peptide nucleic acids. Curr Opin Mol Ther. 2:282–287. 2000.
30.	Soomets U, Hällbrink M and Langel U: Antisense properties of peptide nucleic acids. Front Biosci. 4:D782–D786. 1999. View Article : Google Scholar : PubMed/NCBI
31.	Ray A and Nordén B: Peptide nucleic acid (PNA): its medical and biotechnical applications and promise for the future. FASEB J. 14:1041–1060. 2000.PubMed/NCBI
32.	Tonelli R, Purgato S, Camerin C, Fronza S, et al: Anti-gene peptide nucleic acid specifically inhibits MYCN expression in human neuroblastoma cells leading to persistent cell growth inhibition and apoptosis. Mol Cancer Ther. 4:779–786. 2005. View Article : Google Scholar : PubMed/NCBI
33.	Nielsen PE: Targeting double stranded DNA with peptide nucleic acid (PNA). Curr Med Chem. 8:545–550. 2001. View Article : Google Scholar : PubMed/NCBI
34.	Borgatti M, Lampronti I, Romanelli A, et al: Transcription factor decoy molecules based on a peptide nucleic acid (PNA)-DNA chimera mimicking Sp1 binding sites. J Biol Chem. 278:7500–7509. 2003. View Article : Google Scholar : PubMed/NCBI
35.	Rasmussen FW, Bendifallah N, Zachar V, et al: Evaluation of transfection protocols for unmodified and modified peptide nucleic acid (PNA) oligomers. Oligonucleotides. 16:43–57. 2006. View Article : Google Scholar : PubMed/NCBI
36.	Cortesi R, Mischiati C, Borgatti M, et al: Formulations for natural and peptide nucleic acids based on cationic polymeric submicron particles. AAPS J. 6:10–21. 2004.
37.	Borgatti M, Breda L, Cortesi R, et al: Cationic liposomes as delivery systems for double-stranded PNA-DNA chimeras exhibiting decoy activity against NF-kappaB transcription factors. Biochem Pharmacol. 64:609–616. 2002. View Article : Google Scholar : PubMed/NCBI
38.	Abes R, Arzumanov A, Moulton H, et al: Arginine-rich cell penetrating peptides: design, structureactivity, and applications to alter pre-mRNA splicing by steric-block oligonucleotides. J Pept Sci. 14:455–460. 2008. View Article : Google Scholar : PubMed/NCBI
39.	Torres AG, Threlfall RN and Gait MJ: Potent and sustained cellular inhibition of miR-122 by lysine-derivatized peptide nucleic acids (PNA) and phosphorothioate locked nucleic acid (LNA)/2′-O-methyl (OMe) mixmer anti-miRs in the absence of transfection agents. Artificial DNA PNA XNA. 2:71–78. 2011.PubMed/NCBI
40.	Fabani MM and Gait MJ: miR-122 targeting with LNA/2′-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. RNA. 14:336–346. 2008.
41.	Fabani MM, Abreu-Goodger C, Williams D, et al: Efficient inhibition of miR-155 function in vivo by peptide nucleic acids. Nucleic Acids Res. 38:4466–4475. 2010. View Article : Google Scholar : PubMed/NCBI
42.	Yan LX, Wu QN, Zhang Y, et al: Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res. 13:R22011. View Article : Google Scholar : PubMed/NCBI
43.	Bianchi N, Zuccato C, Lampronti I, Borgatti M and Gambari R: Expression of miR-210 during erythroid differentiation and induction of gamma-globin gene expression. BMB Rep. 42:493–499. 2009. View Article : Google Scholar : PubMed/NCBI
44.	Fabbri E, Manicardi A, Tedeschi T, et al: Modulation of the biological activity of microRNA-210 with peptide nucleic acids (PNAs). Chem Med Chem. 6:2192–2202. 2011. View Article : Google Scholar : PubMed/NCBI
45.	Mizuma M, Katayose Y, Yamamoto K, et al: Up-regulated p27Kip1 reduces matrix metalloproteinase-9 and inhibits invasion of human breast cancer cells. Anticancer Res. 28(5A): 2669–2677. 2008.PubMed/NCBI
46.	Manicardi A, Calabretta A, Bencivenni M, Tedeschi T, Sforza S, Corradini R and Marchelli R: Affinity and selectivity of C2- and C5-substituted ‘chiral-box’ PNA in solution and on microarrays. Chirality. 22(Suppl 1): E161–E172. 2010.PubMed/NCBI
47.	Cailleau R, Olivé M and Cruciger QV: Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro. 14:911–915. 1978. View Article : Google Scholar : PubMed/NCBI
48.	Brown I, Shalli K, McDonald SL, Moir SE, Hutcheon AW, Heys SD and Schofield AC: Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells. Breast Cancer Res. 6:R601–R607. 2004. View Article : Google Scholar : PubMed/NCBI
49.	Faccini A, Tortori A, Tedeschi T, et al: Circular dichroism study of DNA binding by a potential anticancer peptide nucleic acid targeted against the MYCN oncogene. Chirality. 20:494–500. 2008. View Article : Google Scholar : PubMed/NCBI
50.	Suzuki T, Wu D, Schlachetzki F, Li JY, Boado RJ and Pardridge WM: Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. J Nucl Med. 45:1766–1775. 2004.PubMed/NCBI
51.	Pardridge WM, Boado RJ and Kang YS: Vector-mediated delivery of a polyamide (‘peptide’) nucleic acid analogue through the blood-brain barrier in vivo. Proc Natl Acad Sci USA. 92:5592–5596. 1995.PubMed/NCBI
52.	Adlerz L, Soomets U, Holmlund L, Viirlaid S, Langel U and Iverfeldt K: Down-regulation of amyloid precursor protein by peptide nucleic acid oligomer in cultured rat primary neurons and astrocytes. Neurosci Lett. 336:55–59. 2003. View Article : Google Scholar : PubMed/NCBI